RNA Analytical/Quality Videos

81. What Learnings Can mRNA Take From The Oligonucleotide Regulatory Paradigm? 5/10/2024

    ReciBioPharm’s Melanie Cerullo shares where mRNA needs to “catch up” to its oligonucleotide “cousin” molecules and where regulatory differences may be emerging between modalities.

82. Strategies To De-Risk Next-Gen mRNA Raw Materials 12/3/2025

    In this Advancing RNA Live clip, Khaled Yamout and Sanofi’s Francoise Ribes share the quality considerations that are top of mind when evaluating a novel raw material, as well as how the broader industry (i.e., standard setting organizations, suppliers, and biotechs) can arrive at a clearer understanding of a material’s quality.

83. Bridging the Gap Between Analytical Control & Translation 6/9/2026

    Though we may have increasingly clear understandings of our mRNA-LNP products structurally, understanding our products’ cellular function remains challenging without extensive clinical data. Here, this Advancing RNA panel featuring AbbVie’s Elaine Peters, Tessera’s Ilya Shestopalov, and Sanofi’s Philippe Talaga addresses what innovation — both in research and method development — can help us get more functional information about our molecules as we wait for more clinical development.  

84. In Which Specific Areas Do mRNA Makers Need More Regulatory Guidance? 5/10/2024

    Experts from this Advancing RNA Live panel discuss the results from a poll question revealing the top three areas RNA industry experts would be most interested in seeing additional mRNA-specific guidance from regulatory agencies.

85. Rfc Endotoxin Testing: A Sustainable Alternative To LAL 9/24/2026

    Recombinant Factor C testing offers a pharmacopeia-recognized, animal-free alternative to LAL with fewer interference risks, but regulatory hesitation slows adoption across the industry.

86. The Purification Dilemma: Balancing Upstream & Downstream Investment 10/15/2025

    This Advancing RNA Live clip dives into the biggest challenges in mRNA purification and the critical debate on where to focus investment. Here, our three mRNA PD experts argue for a holistic process development strategy, challenging the traditional wisdom of optimizing the upstream process at any cost.

87. LC/MS/MS Analysis Of Coproporphyrin 1, Coproporphyrin 3 In Human Plasma 2/17/2025

    This innovative approach holds promise for reducing the need for extensive clinical drug-drug interaction studies, potentially streamlining the drug development process.

88. The 20-Method Hurdle: Confronting the Operational Burden of mRNA Release 6/9/2026

    Though this Advancing RNA Live panel believes we’re still at too early a stage to begin reducing the number of methods we need for release, Sanofi’s Philippe Talaga, AbbVie’s Elaine Peters, and Tessera’s Ilya Shestopalov had a few ideas on what we can/should be doing today to set us up for more streamlined release panels in the future.  

89. When To Apply GMP Principles For pDNA For mRNA Production 10/29/2026

    In this Advancing RNA clip, the panel tackles an audience question about when GMP principles should apply to pDNA. 

90. LC/TOF Enhanced: Effortless Power, Robustness With Dual-Platform 10/29/2026

    High-resolution time-of-flight mass spectrometry is moving beyond specialist core labs. Full-scan speed, accurate mass, and shared data platforms connect method development to routine QA/QC.